Literature DB >> 17593354

Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort.

Ute Gödtel-Armbrust1, Annegret Metzger, Ulrike Kroll, Olaf Kelber, Leszek Wojnowski.   

Abstract

St. John's wort (SJW, Hypericum perforatum) is a well-tolerated herbal medicine widely used for the treatment of mild and moderate depressions. In the last 5 years, SJW has been implicated in drug interactions, which are largely mediated by the induction of the drug metabolizing enzymes, especially CYP3A4. There is still some controversy regarding the exact mechanism of induction and the identity of the SJW constituents involved. We investigated in LS174T cells the induction of CYP3A4 by ten SJW extracts, six commercial preparations, and the purified SJW constituent hyperforin. The content of hyperforin among the commercial preparations of SJW varied 62-fold (range 0.49-30.57 mg/dose). The CYP3A4 induction was mediated by PXR, but not by CAR. The magnitude of the induction correlated statistically significantly with the content of hyperforin in commercial SJW preparations (R = 0.87, p = 0.004) and in dry extracts (R = 0.65, p = 0.03), but not with their content of flavonoids or hypericin. Most of the CYP3A4 induction response occurred in the hyperforin range encountered in the blood of patients treated with SJW preparations. A temperature-induced decrease in the hyperforin content of a selected dry SJW extract abolished the induction of CYP3A4. In conclusion, commercial SJW preparations still exhibit an enormous variability in CYP3A4 induction, which is mediated by hyperforin and PXR. SJW preparations with lower hyperforin content should reduce the frequency of clinical interactions involving this herbal drug.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593354     DOI: 10.1007/s00210-007-0172-8

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.195


  25 in total

1.  Acute heart transplant rejection due to Saint John's wort.

Authors:  F Ruschitzka; P J Meier; M Turina; T F Lüscher; G Noll
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

Review 2.  St John's wort (Hypericum perforatum): drug interactions and clinical outcomes.

Authors:  L Henderson; Q Y Yue; C Bergquist; B Gerden; P Arlett
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

3.  The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Bernhard Uehleke; Sebastian Klammt; Ralf G Mundkowski; Wolfram Miekisch; Hartwig Sievers; Steffen Bauer; Bruno Frank; Guenther Kundt; Bernd Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2005-12-10       Impact factor: 2.953

4.  An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway.

Authors:  S A Kliewer; J T Moore; L Wade; J L Staudinger; M A Watson; S A Jones; D D McKee; B B Oliver; T M Willson; R H Zetterström; T Perlmann; J M Lehmann
Journal:  Cell       Date:  1998-01-09       Impact factor: 41.582

5.  Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.

Authors:  Oliver Burk; Katja A Arnold; Andreas K Nussler; Elke Schaeffeler; Ekaterina Efimova; Bonnie A Avery; Mitchell A Avery; Martin F Fromm; Michel Eichelbaum
Journal:  Mol Pharmacol       Date:  2005-03-10       Impact factor: 4.436

6.  Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin.

Authors:  A Geick; M Eichelbaum; O Burk
Journal:  J Biol Chem       Date:  2001-01-31       Impact factor: 5.157

Review 7.  MDR- and CYP3A4-mediated drug-herbal interactions.

Authors:  Dhananjay Pal; Ashim K Mitra
Journal:  Life Sci       Date:  2006-01-25       Impact factor: 5.037

Review 8.  Role of hyperforin in the pharmacological activities of St. John's Wort.

Authors:  Paola Zanoli
Journal:  CNS Drug Rev       Date:  2004

9.  Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.

Authors:  Bernard J Komoroski; Shimin Zhang; Hongbo Cai; J Matthew Hutzler; Reginald Frye; Timothy S Tracy; Stephen C Strom; Thomas Lehmann; Catharina Y W Ang; Yan Yan Cui; Raman Venkataramanan
Journal:  Drug Metab Dispos       Date:  2004-05       Impact factor: 3.922

10.  The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer.

Authors:  Matthias Bros; Xiao-Lan Ross; Andrea Pautz; Angelika B Reske-Kunz; Ralf Ross
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

View more
  12 in total

Review 1.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

2.  Protective effects of St. John's wort in the hepatic ischemia/reperfusion injury in rats.

Authors:  Süleyman Atalay; Belkıs Soylu; Aslı Aykaç; Ayliz Velioğlu Öğünç; Şule Çetinel; Naziye Özkan; Can Erzik; Ahmet Özer Şehirli
Journal:  Turk J Surg       Date:  2018-08-28

3.  Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

4.  No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Ralf G Mundkowski; Bernhard Uehleke; Sebastian Klammt; Hartwig Sievers; Romanus Lehnfeld; Bruno Frank; Kerstin Thurow; Guenther Kundt; Bernd Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2008-09-03       Impact factor: 2.953

Review 5.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).

Authors:  Sompon Wanwimolruk; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-04-02       Impact factor: 4.068

6.  St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.

Authors:  Liane Will-Shahab; Steffen Bauer; Ullrich Kunter; Ivar Roots; Axel Brattström
Journal:  Eur J Clin Pharmacol       Date:  2008-11-18       Impact factor: 2.953

7.  Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4.

Authors:  Dieudonné Nem; Dorothea Baranyai; Huan Qiu; Ute Gödtel-Armbrust; Sebastian Nestler; Leszek Wojnowski
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

8.  Structural and functional similarity of amphibian constitutive androstane receptor with mammalian pregnane X receptor.

Authors:  Marianne Mathäs; Christian Nusshag; Christian Nuβhag; Oliver Burk; Ute Gödtel-Armbrust; Holger Herlyn; Leszek Wojnowski; Björn Windshügel
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

9.  Clinically relevant safety issues associated with St. John's wort product labels.

Authors:  Kevin A Clauson; Marile L Santamarina; Jennifer C Rutledge
Journal:  BMC Complement Altern Med       Date:  2008-07-17       Impact factor: 3.659

Review 10.  Hepatotoxicity of Herbal Supplements Mediated by Modulation of Cytochrome P450.

Authors:  Christopher Trent Brewer; Taosheng Chen
Journal:  Int J Mol Sci       Date:  2017-11-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.